Microbot Medical (MBOT) EBITDA Margin (2010 - 2026)

Microbot Medical (MBOT) posted EBITDA Margin of 4114.29% for Q1 2026, down 2903.13% on a QoQ basis from 137.0% in Q1 2017.

Microbot Medical (MBOT) EBITDA Margin (2010 - 2026) Analysis & Trends

Microbot Medical's EBITDA Margin history runs 9 years deep, the most recent figure standing at 4114.29% for Q1 2026.

Quarterly EBITDA Margin changed N/A year-over-year to 4114.29% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 1376.38% (changed N/A YoY) and the FY2017 annual result came in at 2942.46%, up 746593.0% from the prior year.
EBITDA Margin was 4114.29% for Q1 2026 at Microbot Medical, down from 137.0% in the prior quarter.
Across five years, EBITDA Margin topped out at 4114.29% in Q1 2026 and bottomed at 4114.29% in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Alcon	32,734,969.19 Bn	32,734,967.53 Bn	1.53 Bn	98.77%
2	Intuitive Surgical	117.50 Bn	112.41 Bn	1.96 Bn	33.60%
3	Becton Dickinson	42.93 Bn	42.11 Bn	2.15 Bn	1.97%
4	Medline	30.82 Bn	36.66 Bn	1.84 Bn	5.74%
5	Resmed	27.90 Bn	26.23 Bn	890.98 Mn	34.92%
6	West Pharmaceutical Services	26.76 Bn	26.23 Bn	329.20 Mn	20.53%
7	Cooper Companies	15.30 Bn	15.16 Bn	735.40 Mn	-2.87%
8	Solventum	13.46 Bn	12.90 Bn	1.10 Bn	4.04%
9	Align Technology	12.02 Bn	10.96 Bn	736.59 Mn	13.65%
10	Microbot Medical	27.53 Mn	27.53 Mn	2,000.00	-4,114.29%

Download Data